| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
|
Lancet Oncol
|
2008
|
5.21
|
|
2
|
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
|
J Clin Oncol
|
2012
|
3.44
|
|
3
|
Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.
|
J Clin Oncol
|
2005
|
2.90
|
|
4
|
Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma.
|
Ann Surg Oncol
|
2007
|
2.11
|
|
5
|
Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions.
|
Scand J Gastroenterol
|
2009
|
1.75
|
|
6
|
Comparative analysis of five-year survival results of laparoscopy-assisted gastrectomy versus open gastrectomy for advanced gastric cancer: a case-control study using a propensity score method.
|
Dig Surg
|
2012
|
1.72
|
|
7
|
Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer.
|
BMC Cancer
|
2009
|
1.60
|
|
8
|
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
|
Clin Cancer Res
|
2009
|
1.44
|
|
9
|
Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
|
BMC Cancer
|
2010
|
1.31
|
|
10
|
Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases.
|
World J Gastroenterol
|
2009
|
1.24
|
|
11
|
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
|
Am J Clin Oncol
|
2009
|
1.23
|
|
12
|
Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer.
|
BMC Cancer
|
2008
|
1.11
|
|
13
|
Intensity of tumor budding and its prognostic implications in invasive colon carcinoma.
|
Dis Colon Rectum
|
2005
|
1.11
|
|
14
|
Long term survival results for gastric GIST: is laparoscopic surgery for large gastric GIST feasible?
|
World J Surg Oncol
|
2012
|
1.10
|
|
15
|
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
|
Ann Hematol
|
2009
|
1.06
|
|
16
|
Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
|
Jpn J Clin Oncol
|
2005
|
1.05
|
|
17
|
Tumor budding as a prognostic marker in stage-III rectal carcinoma.
|
Int J Colorectal Dis
|
2007
|
1.05
|
|
18
|
A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
|
Acta Oncol
|
2007
|
1.04
|
|
19
|
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
|
Biomarkers
|
2010
|
0.98
|
|
20
|
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
|
Jpn J Clin Oncol
|
2007
|
0.98
|
|
21
|
Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer.
|
Oncol Rep
|
2009
|
0.98
|
|
22
|
Primary penile diffuse large B cell lymphoma treated by local excision followed by rituximab-containing chemotherapy.
|
Acta Haematol
|
2008
|
0.97
|
|
23
|
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
|
Invest New Drugs
|
2009
|
0.96
|
|
24
|
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.
|
Invest New Drugs
|
2010
|
0.96
|
|
25
|
Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine.
|
World J Gastroenterol
|
2006
|
0.96
|
|
26
|
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
|
Oncol Rep
|
2009
|
0.96
|
|
27
|
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
|
Am J Clin Oncol
|
2009
|
0.95
|
|
28
|
A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
|
Invest New Drugs
|
2010
|
0.93
|
|
29
|
15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation.
|
Apoptosis
|
2007
|
0.92
|
|
30
|
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
|
Am J Clin Oncol
|
2010
|
0.91
|
|
31
|
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
|
Jpn J Clin Oncol
|
2007
|
0.90
|
|
32
|
Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.
|
Ann Hematol
|
2006
|
0.90
|
|
33
|
Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer.
|
Cancer Res Treat
|
2005
|
0.89
|
|
34
|
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
|
Acta Oncol
|
2011
|
0.89
|
|
35
|
Extraskeletal mesenchymal chondrosarcoma of the heart responded to systemic chemotherapy: a case report.
|
Cancer Res Treat
|
2007
|
0.87
|
|
36
|
A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis.
|
Cancer Res Treat
|
2011
|
0.85
|
|
37
|
Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide.
|
Korean J Hematol
|
2010
|
0.84
|
|
38
|
A case of 5-fluorouracil induced encephalopathy.
|
Cancer Res Treat
|
2010
|
0.84
|
|
39
|
Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
|
Chemotherapy
|
2013
|
0.83
|
|
40
|
A case of pathologic splenic rupture as the initial manifestation of acute myeloid leukemia M2.
|
Yonsei Med J
|
2009
|
0.83
|
|
41
|
The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
|
BMC Cancer
|
2013
|
0.82
|
|
42
|
Unusual presentation of large B cell lymphoma- bone and stomach- treated with autologous transplantation.
|
Cancer Res Treat
|
2007
|
0.82
|
|
43
|
Nongastric marginal zone B-cell lymphoma: analysis of 247 cases.
|
Am J Hematol
|
2007
|
0.82
|
|
44
|
Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes.
|
J Breast Cancer
|
2011
|
0.81
|
|
45
|
Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma.
|
Cancer Res Treat
|
2005
|
0.81
|
|
46
|
Predictive value of in vitro adenosine triphosphate-based chemotherapy response assay in advanced gastric cancer patients who received oral 5-Fluorouracil after curative resection.
|
Cancer Res Treat
|
2011
|
0.81
|
|
47
|
Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study.
|
Cancer Lett
|
2007
|
0.81
|
|
48
|
Early detection of recurrence after endoscopic treatment for early gastric cancer.
|
Scand J Gastroenterol
|
2009
|
0.80
|
|
49
|
US screening for detection of nonpalpable locoregional recurrence after mastectomy.
|
Eur J Radiol
|
2012
|
0.80
|
|
50
|
Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis.
|
Cancer Res Treat
|
2008
|
0.79
|
|
51
|
Patient perception of natural orifice transluminal endoscopic surgery in an endoscopy screening program in Korea.
|
Yonsei Med J
|
2012
|
0.78
|
|
52
|
Bloodless cancer treatment results of patients who do not want blood transfusion: single center experience of 77 cases.
|
Support Care Cancer
|
2009
|
0.78
|
|
53
|
Homing-associated cell adhesion molecules and cell cycle status on the nucleated cells in the bone marrow, mobilized peripheral blood and cord blood.
|
J Korean Med Sci
|
2004
|
0.78
|
|
54
|
The clinical characteristics and treatment results of ocular adnexal lymphoma.
|
Korean J Ophthalmol
|
2006
|
0.78
|
|
55
|
Impact of the new AJCC staging system and adjuvant treatment in rectal cancer.
|
Cancer Res Treat
|
2004
|
0.78
|
|
56
|
Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease.
|
Eur J Haematol
|
2007
|
0.78
|
|
57
|
Stem cells expressing homing receptors could be expanded from cryopreserved and unselected cord blood.
|
J Korean Med Sci
|
2004
|
0.78
|
|
58
|
Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy.
|
Leuk Res
|
2009
|
0.78
|
|
59
|
Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer.
|
Cancer Res Treat
|
2008
|
0.78
|
|
60
|
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
|
Invest New Drugs
|
2010
|
0.77
|
|
61
|
Prognostic implication of metastatic lymph node ratio in node-positive rectal cancer.
|
J Korean Surg Soc
|
2011
|
0.77
|
|
62
|
Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome.
|
Korean J Hematol
|
2012
|
0.77
|
|
63
|
Polymorphisms and haplotypes in the XRCC1 gene and the risk of advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.77
|
|
64
|
A phase II study of paclitaxel and cisplatin as salvage therapy for patients with advanced or metastatic gastric cancer.
|
Cancer Res Treat
|
2007
|
0.75
|
|
65
|
Expressions of matrix metalloproteinase-7 and -9 and their prognostic significances in rectal cancer.
|
Cancer Res Treat
|
2005
|
0.75
|
|
66
|
Incidence and clinical characteristics of clonal cytogenetic abnormalities of acquired aplastic anemia in adults.
|
Korean J Hematol
|
2010
|
0.75
|
|
67
|
A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study.
|
Cancer Res Treat
|
2004
|
0.75
|
|
68
|
Improvement of the WHO classification-based prognostic scoring system (WPSS) by including age for Korean patients with the myelodysplastic syndrome.
|
Leuk Res
|
2010
|
0.75
|
|
69
|
Urokinase could increase the yield of progenitor cells during red cell depletion in elapsed and anticoagulated cord blood.
|
Am J Hematol
|
2002
|
0.75
|